Clinical trials: Cohort
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDS
Indication:Relapsed or refractory AML in patients for whom no established treatment options are available (this indication will heretofore be referred to as the protocol AML indication), or adult patients with MDS who are…
- Trial name
- NCT04743115
- Testing
- BS HH 002.SA
- Volunteers
- 66 people
- Sponsor
- Shanghai Bensen Pharmaceutical Co., Ltd.
Macular Edema, Retinal Vein Occlusion
An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
This is an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported separately under FVF3426g, NCT00379795) enrolled subjects with primary or recurrent…
- Trial name
- NCT01442064
- Testing
- Ranibizumab 0.5 mg
- Volunteers
- 608 people
- Sponsor
- Genentech, Inc.
Metastatic Breast Cancer
Management of Metastatic Breast Cancer in Clinical Practice - Retrospective Study
The purpose of this study is to evaluate the incidence rate of progression of disease, to describe the diagnostic and clinical management in patients with Metastatic Breast Cancer in the clinical practice in Bulgaria.
- Trial name
- NCT01715155
- Where
- 6 sites in Bulgaria
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
Gastrointestinal Cancer, Metastatic
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
This study is open to adults with advanced colorectal cancer or with advanced pancreatic cancer. The study has 2 parts. In the first part, participants with colorectal cancer get a medicine called BI 905711 combined with…
- Trial name
- NCT05087992
- Testing
- BI 905711, FOLFIRI, Bevacizumab
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim
Diabetic Foot Ulcer, Amniotic Membrane Placental Allograft
a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers
BIOxHEAL is an investigational placental-derived biologic being evaluated for the treatment of nonhealing diabetic foot ulcers. Adults with type 1 or type 2 diabetes who have a diabetic foot ulcer that has not healed with…
- Conditions
- Diabetic Foot Ulcer, Amniotic Membrane Placental Allograft, Biologic
- Trial name
- AB BIOH - DFU (NCT07852338)
- Testing
- Standard of Care, BIOxHEAL (human amniotic membrane allograft)
- Where
- United States
- Volunteers
- 253 people
- Sponsor
- Applied Biologics, LLC
Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.
- Conditions
- Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer
- Trial name
- NCT04249947
- Testing
- P-PSMA-101 CAR-T cells, Rimiducid
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poseida Therapeutics, Inc.
Myocardial Infarction
Safety Study of Bone Marrow Derived Cells to Treat Damaged Heart Muscle
Certain types of cells located in bone marrow may help the body recover after an injury. These cells may be able to help the body repair heart muscle that has been damaged from a heart attack.
- Trial name
- NCT00361855
- Testing
- NX-CP105
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Neuronyx
Cancer (Solid Tumors), Sarcoma
Salutare One Referral Software Impact on Multi-Disciplinary Team (MDT) Meetings Effectiveness and Safety
Multi-Disciplinary Team (MDT) meetings are crucial for planning patient care in the National Health Service (NHS), but they can be time-consuming and sometimes lack complete patient information.
- Trial name
- NCT07104955
- Testing
- MDT referral and review software
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Salutare Group Ltd.
HIV-1 Infections
Observational Data Analysis in EuroSIDA (MK-0518-058)
The main objective of the study is to monitor health outcomes associated with antiretroviral drugs in a population of HIV-infected patients.
- Trial name
- NCT01078233
- Volunteers
- 6,617 people
- Sponsor
- Merck Sharp & Dohme LLC
Early Pregnancy, Early Pregnancy Loss
EARLY-PREG: A Preconception Cohort Study Based on Counterfactuals to Study Maternal-Embryonic Molecular Interactions
EARLY-PREG is an open-cohort clinical study with a preconception, longitudinal, bidirectional and counterfactual design. The aim of this cohort is to investigate the proteomic signatures of maternal-embryonic communication by…
- Conditions
- Early Pregnancy, Early Pregnancy Loss, Childbirth, Healthy
- Trial name
- EARLY-PREG (NCT07358026)
- Testing
- EMBRYO EXPOSURE
- Where
- Chile
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- MELISA Institute Genomics & Proteomics Research SpA
Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease
Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
This example study evaluates the safety, tolerability, and preliminary anti-tumor activity of investigational, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell products for patients with advanced pancreatic…
- Trial name
- DUAL-NK-PDAC (NCT07480928)
- Testing
- EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodepleting chemotherapy (Flu/Cy)
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Multiple Sclerosis
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients
Part 1 of this study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VT7208 in healthy volunteers.
- Trial name
- NCT07085507
- Testing
- VT7208
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Vidya Therapeutics Inc
Pelvic Organ Prolapse
Long-term Evaluation of the Efficacy and Safety of Splentis for the Treatment of Primary Apical Pelvic Organ Prolapse
This prospective, multi center cohort trial aims to evaluate the efficacy and safety of hysteropexy using Splentis via the vaginal route in primary uterine prolapse
- Trial name
- SAXO (NCT05042453)
- Testing
- Splentis® POP Tissue Anchoring System
- Where
- 7 sites in Germany
- Volunteers
- 140 people
- Sponsor
- Promedon
Carcinoma, Non-Small-Cell Lung
A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)
This study aims to better understand people who have advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR mutation.
- Trial name
- LuCaRTE (NCT07680907)
- Volunteers
- 250 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Gaucher's Disease Type I, Gaucher's Disease Type III
Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3
Primary Objective: Evaluated the safety and pharmacokinetics of eliglustat in pediatric participants (≥2 to <18 years old). Secondary Objective: Evaluated the efficacy of eliglustat and quality of life in pediatric participants…
- Trial name
- ELIKIDS (NCT03485677)
- Testing
- Eliglustat GZ385660, Imiglucerase GZ437843
- Where
- 21 sites in Argentina, Canada and 8 more
- Volunteers
- 57 people
- Sponsor
- Sanofi
Advanced Cervical Cancer
A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy
This is a randomized, double-blind, controlled, parallel-cohort Phase II clinical study, which is planned to enroll 220 subjects with advanced cervical cancer who have failed or cannot tolerate first-line or above platinum-based…
- Trial name
- NCT04590599
- Testing
- IBI310, Sintilimab
- Where
- 2 sites in China
- Volunteers
- 205 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Kidney Transplantation in Highly Sensitized Patients
Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
An open-label post authorization efficacy and safety study evaluating graft failure-free survival at 1-year in highly sensitized end-stage renal disease (ESRD) patients with positive crossmatch (XM) against a deceased donor prior…
- Trial name
- PAES (NCT05369975)
- Testing
- Imlifidase, Normal Transplantation Routine
- Where
- 22 sites in Austria, Belgium and 9 more
- Volunteers
- 113 people
- Sponsor
- Hansa Biopharma AB
Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
This is an observational study in which data already collected from people with chronic heart failure is studied. Chronic HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body as well…
- Trial name
- ROVER Japan (NCT06697353)
- Testing
- vericiguat (BAY 1021189)
- Where
- Japan
- Volunteers
- 4,936 people
- Sponsor
- Bayer
Healthy
Bioequivalence Study For 5 Mg Amlodipine Orally-Disintegrating Tablet
This study is being conducted to determine if 5 mg amlodipine 3rd Orally-Disintegrating (OD) tablet (new formulation) and 5 mg amlodipine 2nd OD tablet (commercial formulation) are bioequivalent.
- Trial name
- NCT01004614
- Testing
- Amlodipine
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Erectile Dysfunction
Pharmacodynamic Study of TPN171H Tablets in Patients With Mild to Moderate Erectile Dysfunction
This study is a randomized, double-blind, placebo-controlled, two-cohort, three-cycle crossover (at least a 5-day cleaning period per cycle), and a multicenter clinical trial design.
- Trial name
- NCT05388825
- Testing
- TPN171H 2.5mg, TPN171H 5mg, TPN171H 10mg
- Where
- 8 sites in China
- Volunteers
- 84 people
- Sponsor
- Vigonvita Life Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.